C. Greene (Dublin, Ireland), M. Gjomarkaj (Palermo, Italy)
Comparing the effects of orally and intranasally administered IKK2 inhibitors in a 4 day tobacco-smoke exposed model of COPD
M. Whitmarsh, A. Connolly, V. Russell, A. Young (Stoke Poges, United Kingdom)
|  |
Mesoporous silica-based nanoparticles for targeted delivery of proteasome inhibitors to the lung
S. H. van Rijt, C. Argyo, D. A. Bölükbas, O. Eickelberg, T. Bein, S. Meiners (Munich, Germany)
| |
Estrogen-regulated miRNA-19b modulates the expression of secretory leukoprotease inhibitor in monocytes
P. McKiernan, S. Chotirmall, S. A. Cryan, N. G. McElvaney, C. Greene (Dublin, Ireland)
|  |
Nanostructured lipid carriers as drug delivery systems for fluticasone propionate: Effects in cigarette smoke stimulated bronchial epithelial cells
M. L. Bondì, M. Ferraro, S. Di Vincenzo, S. Gerbino, G. Cavallaro, G. Giammona, M. Gjomarkaj, E. Pace (Palermo, Italy)
| |
Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis
J. Deacon, S. Abdelghany, S. Elborn, A. Kissenpfennig, C. Taggart, C. Scott (Belfast, United Kingdom)
| |
Exogenous administration of bone marrow-derived stem cells in experimental COPD
B. Lobo, R. Puig-Pey, E. Ferrer, D. Domínguez-Fandos, N. Coll, J. García, C. Bonjoch, J. A. Barberà, V. I. Peinado (Barcelona, Spain)
| |
Comparative effects of inhaled and intravenous mesenchymal stem cells in bleomycin-induced pulmonary fibrosis in rabbits
A. Averyanov, A. Konoplyannikov, F. Zabozlaev, O. Danilevskaya, M. Konoplyannikov, O. Kuzovlev, N. Kulagina, I. Koroleva (Moscow, Obninsk, Russian Federation)
|  |
Fast, efficient and realistic in vitro delivery of inhaled drugs to pulmonary cells: Application to the proteasome inhibitor bortezomib
A. G. Lenz, D. Cei, M. Schmidmeir, N. Pfister, G. Burgstaller, B. Lentner, O. Eickelberg, T. Stöger, O. Schmid, S. Meiners (Munich, Germany)
| |